All > Massachusetts Investigators

Geoffrey Shapiro, MD, PhD

Dana-Farber Cancer Institute

Boston, Massachusetts - 02115

CLINICAL TRIALS 3
CONDITIONS3
INTERVENTIONS3
SINCE2008

AZD6244 in Cancers With BRAF Mutations

April 2009 - April 2012

A Study of the HSP90 Inhibitor STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

November 2009 - September 2011

Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors

May 2008 - June 2011

Lung Neoplasms

Neoplasms

Carcinoma, Non-Small-Cell Lung

Sta 9090

Azd6244

At13387

Learn about TrialX Patient Recruitment services

Massimo Loda, MD

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute

Suzanne Shusterman

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Childrens Hospital Boston, Dana-Farber Cancer Institute. Children's Hospital Boston

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Dana-Farber Cancer Institute Dana Farber / Brigham and Women's Cancer Center Dana-Farber Cancer Institute, Center for Neuro-Oncology Dana-Farber Cancer Instiute

Lewis B. Silverman, MD

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Dana-Farber Cancer Institute and Children's Hospital Dana Faber Cancer Institute, Children's Hospital, Dept. of Pediatric Oncology Children's Hospital Boston Dana-Farber Cancer Institute

Geoffrey Shapiro, MD, PhD

Dana-Farber Cancer Institute

Massimo Loda, MD

Suzanne Shusterman

Patrick Y. Wen, MD

Lewis B. Silverman, MD

Kay Kehoe, Coordinator

Jennifer Brown, MD

Rachel A. Freedman

Edwin P. Alyea, MD

F. Stephen Hodi, MD

Beth A. Overmoyer, MD, FACP